AgomAb (AGMB) Director Naimish Patel Receives 56,328-Share Option Award

What Happened Naimish Patel, a director of AgomAb Therapeutics NV, was granted a derivative award for 56,328 shares on September 11, 2026. The award shows an acquisition at $0.00 (i.e., no cash paid at grant) and is reported as a derivative (option/award) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-11; Form 4 filed: 2026-09-15 (filed four days after the transaction date; note SEC Form 4s are generally required within two business days).
• Shares/units granted: 56,328 (reported at $0.00 at grant; derivative).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting: 33% vests on 2027-09-11; remaining shares vest in 24 equal monthly installments thereafter, subject to continued service (Footnote F3).
• Currency/exercise price: exercise price is reported in USD after conversion from EUR at $1.1616 per EUR (Footnote F2). Exact exercise price amount was not included in the supplied summary.
• ADS note: Common shares may be represented by American Depositary Shares (ADS), each currently representing one common share (Footnote F1).

Context This is a compensation award (derivative grant) rather than a purchase or sale. Such grants are commonly used for director compensation and do not, by themselves, indicate whether the insider is bullish or bearish on the stock. The vesting schedule means the award is tied to continued service; there is no indication the shares were immediately sold or cashed out.